Crohn Disease (CD) Clinical Trials

44 recruitingLast updated: June 18, 2026

There are 44 actively recruiting crohn disease (cd) clinical trials across 20 countries. Studies span Not Applicable, Phase 2, Phase 4, Phase 1, Early Phase 1. Top locations include Amiens, France, Marseille, France, Clermont-Ferrand, France. Updated daily from ClinicalTrials.gov.


Crohn Disease (CD) Trials at a Glance

44 actively recruiting trials for crohn disease (cd) are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Not Applicable with 15 trials, with the heaviest enrollment activity in Amiens, Marseille, and Clermont-Ferrand. Lead sponsors running crohn disease (cd) studies include Asian Institute of Gastroenterology, India, Pontificia Universidad Catolica de Chile, and Shmuel Kivity, MD.

Browse crohn disease (cd) trials by phase

Treatments under study

About Crohn Disease (CD) Clinical Trials

Looking for clinical trials for Crohn Disease (CD)? There are currently 44 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Crohn Disease (CD) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Crohn Disease (CD) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 44 trials

Recruiting
Phase 2

HB-adMSCs for the Treatment of Crohn's Disease

Crohn Disease (CD)
Hope Biosciences Research Foundation46 enrolled1 locationNCT07077746
Recruiting

Impact of Advanced Crohn's Disease Therapies on Sleep Quality

Crohn Disease (CD)
Shmuel Kivity, MD30 enrolled1 locationNCT07649408
Recruiting
Not Applicable

Regenerative Endoscopy in Refractory Perianal Crohn's Disease

Crohn Disease (CD)Perianal Crohns Disease
Asian Institute of Gastroenterology, India50 enrolled2 locationsNCT07652632
Recruiting

Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease

IBD (Inflammatory Bowel Disease)Ulcerative Colitis (UC)Crohn Disease (CD)
Shmuel Kivity, MD40 enrolled1 locationNCT07644117
Recruiting
Phase 4

TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response

Crohn Disease (CD)
Sixth Affiliated Hospital, Sun Yat-sen University312 enrolled1 locationNCT07510191
Recruiting
Not Applicable

Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin

Crohn Disease (CD)Ileocolic ResectionPost-endoscopic Operative Reccurence
University Hospital, Clermont-Ferrand42 enrolled8 locationsNCT06972901
Recruiting
Phase 2

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

Crohn Disease (CD)
Washington University School of Medicine60 enrolled3 locationsNCT06976853
Recruiting
Phase 1Phase 2

Tolerance of Local Administration of Cryopreserved Autologous Stromal Vascular Fraction Combined With Micrograft for the Treatment of Refractory Ano-perineal Fistulas in Crohn's Disease

Crohn Disease (CD)
Assistance Publique Hopitaux De Marseille25 enrolled1 locationNCT07629245
Recruiting

Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context

Ulcerative Colitis (UC)Crohn Disease (CD)
Imelda GI Clinical Research Center100 enrolled1 locationNCT07621783
Recruiting
Not Applicable

A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease

Crohn Disease (CD)
Alimentiv Inc.378 enrolled39 locationsNCT07363044
Recruiting
Phase 4

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

Crohn Disease (CD)
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives75 enrolled6 locationsNCT07292012
Recruiting
Not Applicable

WAter Preparation in Crohn's Disease's Imagery

Crohn Disease (CD)
University Hospital, Toulouse194 enrolled1 locationNCT06690632
Recruiting
Not Applicable

Combining Nutritional Therapy and Anti-TNFα Treatment in Pediatric Patients With Crohn's Disease

IBD (Inflammatory Bowel Disease)Crohn Disease (CD)
University of British Columbia140 enrolled1 locationNCT07314606
Recruiting

Evaluation of Muscle Strength and Muscle Mass in Patients With Inflammatory Bowel Disease

Crohn Disease (CD)
Sakarya University100 enrolled1 locationNCT07441447
Recruiting

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Ulcerative Colitis (UC)Crohn Disease (CD)Inflammatory Bowel Disease (IBD)+1 more
TIDHI Innovation Inc.200 enrolled9 locationsNCT07245394
Recruiting

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

IBD (Inflammatory Bowel Disease)Crohn Disease (CD)IBS - Irritable Bowel Syndrome+1 more
American Laboratory Products Company120 enrolled1 locationNCT07089420
Recruiting
Not Applicable

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Ulcerative Colitis (UC)Crohn Disease (CD)
IRCCS Ospedale San Raffaele80 enrolled1 locationNCT06896305
Recruiting

CEDUR - German IBD Registry

Ulcerative Colitis (UC)Crohn Disease (CD)Indeterminate Colitis
ImmunoRegister gUG10,000 enrolled1 locationNCT07319442
Recruiting
Phase 4

De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

Ulcerative Colitis (UC)Crohn Disease (CD)
McGill University Health Centre/Research Institute of the McGill University Health Centre115 enrolled1 locationNCT07303686
Recruiting

Kinetics of Transmural Healing in Patients With Crohns Disease Treated With Risankizumab (SKYRIZI®)

Crohn Disease (CD)Transmural Response
University Hospital, Clermont-Ferrand100 enrolled4 locationsNCT07308067